Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus. The new findings, from researchers at a number of international institutions including Imperial College London and the Medical Research Council Unit The Gambia, also suggest the initiative is feasible and cost-effective.
27 July 2016 | Eurekalert Inf Dis
Researchers at several different US sites have found that less than one-third of 1% of patients infected with hepatitis B virus (HBV) get rid of the virus per year, and overall, only 1.2% of patients finally get rid of it.
12 July 2016 | Eurekalert Inf Dis
A discovery of the process by which the hepatitis B virus matures inside the body helps to explain why the virus is much more potent that others in causing infection, and how it so effectively targets the liver.
22 June 2016 | Hepatitis News Today
Patients with hepatitis delta virus infection treated with pegylated interferon alpha were less likely to develop clinical outcomes — like decompensation or hepatocellular carcinoma — compared with patients who received nucleos(t)ide based treatment or no treatment at all, according to a presentation at International Liver Congress.
22 April 2016 | Healio
Viral rebound studies showed that CMX157 demonstrates best-in-class duration of activity. Nine days following incubation with HBV, using two different experimental conditions, one at equimolar and one at EC90 concentrations, CMX157 showed two- to three-fold reduced viral rebound compared to TAF.
30 March 2016 | ContraVir press release
The deal with Sino's Chia Tai Tiaqing Pharmaceutical unit includes an immune-stimulating agent that could potentially be combined with antiviral drugs J&J acquired when it purchased Novira Therapeutics in November. Hepatitis B has been difficult to cure because antiviral medicines that block replication of the virus have proved insufficient at clearing it from the blood. J&J and other researchers believe an assault by components of the immune system will be needed as part of a cure.
08 January 2016 | Reuters
Bollywood megastar Amitabh Bachchan made a startling revelation about surviving only on 25 per cent of his liver today having lost the rest 75 percent to the deadly Hepatitis B virus. Speaking at the launch of media campaign for on Hepatitis, Amitabh Bachchan recollected how he contracted the disease.
24 November 2015 | The Indian Express
A cohort study involving 2,400 men who have sex with men has shown that men with HIV who were treated effectively with HIV therapy — defined as no detectable HIV virus in the blood — were the least likely (80 percent less likely) to get infected with HBV over a median follow-up of approximately 9.5 years, compared with men with HIV who were not on HIV therapy or men who had detectable HIV virus while on HIV therapy.
13 October 2015 | Johns Hopkins Medicine
The Company believes CMX157's lipid-conjugate design clearly differentiates it from tenofovir DF. ContraVir plans to file an investigational new drug (IND) application for CMX157 to treat HBV before year-end 2015. CMX157 benefits from earlier human studies in volunteers under an IND for HIV. ContraVir is focused on a quick evaluation of CMX157 in a Phase 2 clinical study in patients with hepatitis B which it plans to begin in 2016.
06 October 2015 | Contravir press release
Gilead Sciences Inc., basking in the success of its cure for hepatitis C, is setting ambitious goals to vanquish two other major viral scourges: HIV and hepatitis B.
19 August 2015 | Bloomberg